UPPMD is a partner in the Vision-DMD project. The Vision-DMD project will undertake Phase 2a and 2b clinical trials investigating the safety and efficacy of Vamorolone (VBP15) in ambulant Duchenne muscular dystrophy (DMD) boys. This project builds on positive preclinical and Phase 1 results in healthy adult volunteers. Vision-DMD is an advanced and innovative clinical programme to develop a safe, effective and affordable therapy for DMD.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 667078.

On February 17th 2017 the Vision-DMD Workshop on Standards of Care has taken place in Rome. The workshop has been recorded, please see below the full workshop.